Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma

被引：1
|
作者：
Mistry, Kavita [1 ,2 ]
Zhao, Sophia [3 ]
Strohbehn, Ian [4 ]
Wang, Qiyu [4 ]
Hanna, Paul [4 ,5 ]
Strohbehn, Samuel [4 ]
Katz-Agranov, Nurit [4 ]
Sullivan, Ryan J. [6 ]
Sise, Meghan E. [4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[3] Analyt Now LLC, Brookline, MA USA
[4] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA
[5] Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI USA
[6] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷 / 06期
关键词：
METASTATIC MELANOMA; DOUBLE-BLIND; OPEN-LABEL; VEMURAFENIB; PHASE-3; MULTICENTER; DABRAFENIB; TRAMETINIB; PLACEBO; ENCORAFENIB;
D O I：
10.1093/ndt/gfae049
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
10.1093/ndt/gfae049 Video Watch the video of this contribution at https://academic.oup.com/ndt/pages/author_videos gfae049Media1 6348384678112
引用
收藏
页码：1040 / 1043
页数：4
相关论文
共 50 条
  • [1] BRAF and MEK inhibitors in BRAF-mutant melanoma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (11): : E468 - E468
  • [2] Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors
    Carbonnel, Franck
    Routier, Emilie
    Lazure, Thierry
    Mussini, Charlotte
    Bellanger, Christophe
    Merklen, Carine
    Bejou, Bakhtiar
    Buisson, Anthony
    Amiot, Aurelien
    Meyer, Antoine
    Dong, Catherine
    Robert, Caroline
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (07) : 792 - 799
  • [3] Resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma
    Patel, Hima
    Yacoub, Nour
    Garrett, Joan T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB43 - AB43
  • [4] BRAF and MEK inhibitors in therapy of advanced melanoma
    Kosela, Hanna
    Switaj, Tomasz
    Rutkowski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (05): : 246 - 253
  • [5] High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
    Fizazi, Ariane
    Serrand, Chris
    Evrard, Alexandre
    Bergeret, Blanche
    Stoebner, Pierre-Emmanuel
    Marque, Myriam
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [6] Chemotherapy in patients with metaststic melanoma after progression on BRAF/MEK inhibitors
    Samoylenko, I. V.
    Kharkevich, G.
    Demidov, L. V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
    Cybulska-Stopa, Bozena
    Rogala, Pawel
    Czarnecka, Anna M.
    Galus, Lukasz
    Dziura, Robert
    Rajczykowski, Marcin
    Kubiatowski, Tomasz
    Wisniewska, Magdalena
    Gega-Czarnota, Adrianna
    Teterycz, Pawel
    Ziobro, Marek
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    MELANOMA RESEARCH, 2020, 30 (05) : 465 - 471
  • [8] Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma
    Sada, Ikuyo
    Harada, Yosuke
    Hiyama, Tomona
    Mizukami, Mina
    Kan, Takanobu
    Kawai, Mikio
    Kiuchi, Yoshiaki
    MELANOMA RESEARCH, 2023, 33 (06) : 539 - 546
  • [9] Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma
    Sibaud, Vincent
    Baric, Lilian
    Cantagrel, Alain
    Di Palma, Mario
    Ederhy, Stephane
    Paques, Michel
    Perlemuter, Gabriel
    BULLETIN DU CANCER, 2021, 108 (05) : 528 - 543
  • [10] BRAF and MEK Inhibitors Offer Good News in Melanoma
    不详
    CANCER DISCOVERY, 2012, 2 (07)
12345